Xyphos and Poseida to develop allogeneic cell therapies for cancer
Pharmaceutical Technology
MAY 2, 2024
Xyphos Biosciences and Poseida Therapeutics have signed a deal to develop new allogeneic cell therapies for treating cancer.
allogene 
Allogene Therapeutics gets grant for patent granted for CD19-specific CARS resistant to rituximab
Pharmaceutical Technology
APRIL 23, 2024
Discover the groundbreaking patent by Allogene Therapeutics for CD19-specific CARs resistant to rituximab binding. Learn about the innovative methods and features of these engineered immune cells.
Engineer 
130
130 Engineer 130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
Bio Pharma Dive
MARCH 12, 2024
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
Drugs 171
171 
Allogene starts first pivotal trials of an ‘off-the-shelf’ cell therapy for cancer
Bio Pharma Dive
OCTOBER 7, 2022
The biotech believes the two Phase 2 trials initiated Thursday can support approval applications for what could be the first so-called allogeneic cancer cell therapy.
Trials 319
319 Trials 319
319 
IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma
Pharmaceutical Technology
MARCH 20, 2024
Cellectis presented promising data with UCART20x22, which represents a pioneering allogeneic dual CAR T-cell product designed to target two established antigens.
Production 130
130 Production 130
130 
Allogene cleared by FDA to resume 'off the shelf' cancer cell therapy trials
Bio Pharma Dive
JANUARY 10, 2022
A "chromosomal abnormality" that led regulators to halt Allogene's trials was judged to be unrelated to its technology, a finding with important implications for the field of donor-derived cell therapies.
Trials 355
355 
Allogene cell therapy trials halted by FDA after safety finding
Bio Pharma Dive
OCTOBER 7, 2021
Researchers found evidence of a "chromosomal abnormality" in one patient treated with Allogene's CAR-T cell therapy, spurring the clinical hold and an investigation.
Trials 311
311 
Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune
BioSpace
APRIL 14, 2024
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
Development 106
106 Development 106
106 
Servier cuts ties with Allogene, ending complex CAR-T partnership
Bio Pharma Dive
SEPTEMBER 22, 2022
The French drugmaker terminated a nearly decade-old deal that helped Allogene emerge as the sector's largest "off-the-shelf" cell therapy developer.
Development 206
206 Development 206
206 
Cemacabtagene ansegedleucel by Allogene Therapeutics for Follicular Lymphoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Follicular Lymphoma.
Highlights from the EHA Congress 2023 meeting: allogeneic cell therapy updates
Pharmaceutical Technology
JULY 18, 2023
The development of allogeneic (allo) cell therapies has been a major focus of the biopharmaceutical industry for the last several years.
Development 130
130 Development 130
130 
Cemacabtagene ansegedleucel by Allogene Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).
Cemacabtagene ansegedleucel by Allogene Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL).
Cemacabtagene ansegedleucel by Allogene Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
Cemacabtagene ansegedleucel by Allogene Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Cemacabtagene ansegedleucel by Allogene Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 8, 2024
Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma.
Astellas, Poseida Therapeutics Ink Allogeneic Cell Therapy Agreement
Pharmaceutical Commerce
MAY 3, 2024
Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.
Production 52
52 Production 52
52 
Allogene Initiates First-Ever Phase II Trial of Allogeneic CAR-T Therapy
BioSpace
OCTOBER 6, 2022
Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry. The ALPHA2 trial will evaluate ALLO-501A in LBCL.
Trials 106
106 
$15 million CIRM grant supports allogeneic CAR-T in renal cell carcinoma
Drug Discovery World
MAY 2, 2024
Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of ALLO-316, an AlloCAR T investigational product for the treatment of advanced or metastatic renal cell carcinoma (RCC).
Trials 64
64 
Allogene to shift strategy in bid to reposition CAR-T
Bio Pharma Dive
JANUARY 4, 2024
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
309 
FDA green light for trial of allogeneic regulatory T cell therapy
Drug Discovery World
APRIL 12, 2024
The company plans to initiate a Phase I study of the investigational allogeneic off-the-shelf Tr1 Treg therapy for this indication in the second quarter of 2024. ” “Allogeneic stem cell transplantation is the only curative treatment for many advanced blood cancers and genetic and acquired diseases.
Trials 52
52 
6th Allogeneic Cell Therapies Summit
pharmaphorum
FEBRUARY 15, 2024
The 6th Allogeneic Cell Therapies Summit, driving potency, efficacy & durability of universal cell therapies. Coming to Boston, MA this June 12th-14th 2024.
52 
Allogene, slipping in 'off-the-shelf' CAR-T race, prepares for key trials
Bio Pharma Dive
FEBRUARY 24, 2022
Allogene, once the clear leader in development of a more convenient option to personalized cancer cell therapies, now is competing with CRISPR Therapeutics and other fast-emerging rivals.
Trials 148
148 
UK-Singapore alliance focuses on allogeneic cancer immunotherapy
Drug Discovery World
APRIL 28, 2023
The funding has been awarded to enable the two organisations to carry out a project – valued at £400,000 ($499,000) – which aims to create a broadly-applicable iPSC-derived allogenic immunotherapy platform. The post UK-Singapore alliance focuses on allogeneic cancer immunotherapy appeared first on Drug Discovery World (DDW).
Engineer 98
98 
Leveraging allogeneic dendritic cells for neoantigen cancer vaccines
Medical Xpress
FEBRUARY 3, 2023
A new research perspective was published in Genes & Cancer on January 30, 2023, entitled, "Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines."
Vaccination 90
90 
Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo
Fierce Pharma
DECEMBER 19, 2022
Atara makes history with world-first nod for allogeneic T-cell therapy Ebvallo. fkansteiner. Mon, 12/19/2022 - 14:06.
120 
Precision Announces Promising Data on Potential Allogeneic CAR T Pioneer
BioSpace
JUNE 8, 2022
Precision BioSciences' clinical program exploring allogeneic CAR T therapy may well produce a market pioneer after initial data showed its ability to deliver a 100% overall response rate.
Marketing 90
90 Marketing 90
90 
Topline results support allogeneic cell vaccine in lung cancer
Drug Discovery World
JULY 27, 2023
The Phase I study was a first-in-human trial to investigate safety, immunogenicity, and survival in patients with advanced NSCLC (defined as metastatic or locally advanced disease) when administered the allogeneic dendritic cell (DC) vaccine VAC2.
Vaccination 52
52 
Eterna acquires Exacis’ allogeneic immuno-oncology platform
Drug Discovery World
MAY 5, 2023
The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. The post Eterna acquires Exacis’ allogeneic immuno-oncology platform appeared first on Drug Discovery World (DDW).
Gene Editing 52
52 
Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy
BioSpace
NOVEMBER 11, 2023
The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.
52 
Kite Enters Allogenic Cell Therapy Collab with Startup Appia Bio for $875 Million
BioSpace
AUGUST 4, 2021
Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.
Licensing 103
103 
Poseida Goes All-In on Allogeneic CAR-T; Ligand Explores Spin-Off
BioSpace
NOVEMBER 9, 2021
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
97 
Pfizer backs CRISPR biotech Caribou in latest cell therapy investment
Bio Pharma Dive
JULY 6, 2023
Five years after helping launch Allogene Therapeutics, Pfizer is backing another developer of “off-the-shelf” cell therapies in a deal that gives the drugmaker the chance to acquire a multiple myeloma treatment.
Development 327
327 Development 327
327 
Allogene, Overland Form Joint Venture to Advance Allogenic CAR T Cell Therapies in China
BioSpace
DECEMBER 14, 2020
Clinical-stage biotechnology company Allogene Therapeutics and start-up company Overland Pharmaceuticals are forming a new joint company named Allogene Overland Biopharm.
54 
Charles River Laboratories becomes first CDMO in North America to receive EMA approval for commercial production of allogenic cell therapy drug product
BioPharma Reporter
AUGUST 11, 2022
has received regulatory approval - in the form of Good Manufacturing Practice (GMP) certification - to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European Medicines Agency (EMA). Charles River Laboratories, International Inc.
Production 98
98 
EMA to review Atara's MAA submission for allogeneic T-cell therapy: ‘A watershed moment for the field’
BioPharma Reporter
NOVEMBER 30, 2021
The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.
Marketing 98
98 
Gilead's Kite bets on early-stage biotech to advance allogeneic cell therapies
Bio Pharma Dive
AUGUST 5, 2021
Appia Bio, which launched with over $50 million in Series A funding earlier this year, will provide preclinical research for two CAR-iNKT candidates, which Kite will pick up should they advance past early clinical testing.
Research 288
288 Research 288
288 
Roche digs into off-the-shelf cell therapy with Poseida deal
Bio Pharma Dive
AUGUST 3, 2022
The pharma has now signed two alliances with allogeneic drug developers since September, signalling its interest in CAR-T treatment alternatives.
Development 353
353 
Chromosomal "Abnormality" Forces Allogene to Halt Trial as Shares Crater
BioSpace
OCTOBER 7, 2021
Allogene placed its study on hold after sending a notification to the U.S. FDA about a chromosomal abnormality in its ALPHA2 study patient.
Trials 74
74 Trials 74
74 
FDA halts Allogene CAR-T trial after safety scare
pharmaphorum
OCTOBER 8, 2021
A phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a “chromosomal abnormality” was seen in a patient receiving the cell therapy. Off the shelf or allogeneic cell therapies are derived from a bank of cells and can be manufactured and administered in bulk like drugs.
Trials 52
52 
Allogene shares sink on early look at an 'off the shelf' CAR-T for myeloma
Bio Pharma Dive
NOVEMBER 4, 2020
Results the company will present at a medical meeting, while early, don't appear to meet the high bar set by rival CAR-T cell therapies from Bristol Myers Squibb and Johnson & Johnson.
348 
Precision’s Stealth Cell Allogeneic CAR T Candidate Engineered for Persistence
BioSpace
FEBRUARY 10, 2021
Precision BioSciences recently received a notice of allowance for a new patent for PBCAR19B, its stealth cell, CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma.
Engineer 60
60 Engineer 60
60 
Could placenta-derived cells revolutionize age-related disease treatment?
BioPharma Reporter
APRIL 23, 2024
Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases.
Development 137
137 Development 137
137 
CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
Bio Pharma Dive
OCTOBER 12, 2021
However, safety worries have emerged since the FDA ordered CRISPR's rival Allogene to suspend clinical work. The gene editing company aims to expand its trial and add a second dose to improve effectiveness.
Gene Editing 348
348 
Let's personalize your content